Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan (NEWLAN)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
Jordan
Study Type
Interventional
Intervention
INSULIN GLARGINE
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion criteria :
- Patient ≥ 18 years old.
- Male or Female.
- Type 2 diabetes patients.
- Uncontrolled with previous therapy (HbA1c >7%), evident in HbA1c test within the last 1 month before study entry.
- Insulin naïve patients: any patient uncontrolled after one or a maximum of two lines of therapy including: monotherapy (Metformin alone or any other Oral Anti-Diabetic agent (OAD) if contraindicated or intolerance) and/or dual therapy (any OAD combination), at maximum tolerated dose in the last 3 months.
- Signed informed consent.
- Signed informed consent.
Exclusion criteria:
- Patient not willing or not able to perform self-monitoring blood glucose.
- Patient not willing or not able to self-titrate insulin glargine under physician's guidance.
- Patient not suitable for participation according to what is specified in the approved Summary of Product's Characteristics or according to medical or clinical conditions, as judged by the Investigator.
- History of impaired hepatic function defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than three times the upper limit of normal, evident in testing done in the last 3 months.
- History of impaired renal function defined as serum creatinine >135 μmol/L (>1.525 mg/dL)in men and >110 μmol/L (>1.243 mg/dL) in women, evident in testing done in the last 3 months.
- Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method at physician's discretion).
- Treatment with systemic corticosteroid within 3 months prior to study entry.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- JORDAN
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
HOE901
Arm Description
HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
Outcomes
Primary Outcome Measures
Change from baseline in HbA1c
Secondary Outcome Measures
- Percentage of patients achieving target of HbA1c <7%
- Change from baseline in fasting plasma glucose values
- Percentage of patients with hypoglycemic events
- Change from baseline in body weight
- Number of patients with adverse events
- Change in dose of insulin glargine
- Change in the titration doses used (if any)
- Time to reach control
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02606357
Brief Title
Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
Acronym
NEWLAN
Official Title
Treatment Initiation With Basal Insulin in Uncontrolled Type 2 Diabetes Patients on Oral Anti-Diabetic Agent (OAD) in Jordan
Study Type
Interventional
2. Study Status
Record Verification Date
October 2018
Overall Recruitment Status
Completed
Study Start Date
November 22, 2015 (Actual)
Primary Completion Date
November 27, 2017 (Actual)
Study Completion Date
November 27, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sanofi
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Primary Objective:
-To assess the change in glycosylated hemoglobin (HbA1c) in uncontrolled Type 2 diabetes patients on OAD agent in Jordan after 6 months of treatment with basal insulin (Insulin glargine).
Secondary Objectives:
To evaluate the percentage of patients achieving target of HbA1c ˂7%.
To evaluate the change in fasting plasma glucose (FPG).
To assess the following safety criteria: hypoglycemic events, body weight changes, and overall safety.
Describe the titration process: changes in glargine insulin dose at 3 months and 6 months, changes in the titration doses used (if any), and time to reach control.
Detailed Description
The total duration of study period per patient is up to 6 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
242 (Actual)
8. Arms, Groups, and Interventions
Arm Title
HOE901
Arm Type
Experimental
Arm Description
HOE901 administered subcutaneously once a day in the evening, at dinner, or at bedtime with titration based on FPG levels
Intervention Type
Drug
Intervention Name(s)
INSULIN GLARGINE
Other Intervention Name(s)
HOE901
Intervention Description
Pharmaceutical form:Solution
Route of administration: Subcutaneous
Primary Outcome Measure Information:
Title
Change from baseline in HbA1c
Time Frame
Baseline, 6 months
Secondary Outcome Measure Information:
Title
- Percentage of patients achieving target of HbA1c <7%
Time Frame
6 months
Title
- Change from baseline in fasting plasma glucose values
Time Frame
Baseline, 3 months, and 6 months
Title
- Percentage of patients with hypoglycemic events
Time Frame
Baseline, 6 months
Title
- Change from baseline in body weight
Time Frame
Baseline, 3 months and 6 months
Title
- Number of patients with adverse events
Time Frame
Baseline, 6 months
Title
- Change in dose of insulin glargine
Time Frame
3 months and 6 months
Title
- Change in the titration doses used (if any)
Time Frame
6 months
Title
- Time to reach control
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria :
Patient ≥ 18 years old.
Male or Female.
Type 2 diabetes patients.
Uncontrolled with previous therapy (HbA1c >7%), evident in HbA1c test within the last 1 month before study entry.
Insulin naïve patients: any patient uncontrolled after one or a maximum of two lines of therapy including: monotherapy (Metformin alone or any other Oral Anti-Diabetic agent (OAD) if contraindicated or intolerance) and/or dual therapy (any OAD combination), at maximum tolerated dose in the last 3 months.
Signed informed consent.
Signed informed consent.
Exclusion criteria:
Patient not willing or not able to perform self-monitoring blood glucose.
Patient not willing or not able to self-titrate insulin glargine under physician's guidance.
Patient not suitable for participation according to what is specified in the approved Summary of Product's Characteristics or according to medical or clinical conditions, as judged by the Investigator.
History of impaired hepatic function defined as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) greater than three times the upper limit of normal, evident in testing done in the last 3 months.
History of impaired renal function defined as serum creatinine >135 μmol/L (>1.525 mg/dL)in men and >110 μmol/L (>1.243 mg/dL) in women, evident in testing done in the last 3 months.
Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method at physician's discretion).
Treatment with systemic corticosteroid within 3 months prior to study entry.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Sciences & Operations
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
JORDAN
City
Jordan
Country
Jordan
12. IPD Sharing Statement
Learn more about this trial
Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
We'll reach out to this number within 24 hrs